With so many biotech stocks making big moves and pharmaceutical merger activity moving faster than anything else right now, we turned to one of the smartest analysts in the lucrative biotech field to give us his take on what we should be doing…

New breakthroughs in adult stem cell technology offer staggering implications for medical science, says Patrick Cox. And a massive opportunity for investors. As Big Pharma move in, Patrick says biotech companies involved in stem cell research and RNA technology could become the “investment of a lifetime.”

It’s no secret I’m a Big Pharma bear. And my favorite target is Pfizer, the world’s largest drug company.

One of the drug industry’s biggest superstars right now is a cancer drug called Sutent.

Pfizer – the biggest pharmaceutical company in the world – is the cheapest it’s ever been in recorded history.

The Dow and most foreign stock-markets enjoyed a blistering rally on Wednesday but heading into yesterday morning’s trade the futures look pretty ugly.

Back in December, I told you the bleak story of Neurocrine Biosciences (NBIX). A week earlier, the company had received a crushing blow from the FDA, dished out in a notorious “approvable letter.” Approvable letters are the FDA’s way of turning a “yes/no” decision on a new drug into a “maybe.”